AU2021293943A1 — SMARCA4 inhibition for the treatment of cancer
Assigned to Epizyme Inc · Expires 2023-02-23 · 3y expired
What this patent protects
The present disclosure provides methods of determining a response to at least one therapy by a subject having cancer, wherein the at least one therapy comprises the administration of at least one SMARCA4-targeting compound. The present disclosure also provides methods of treating…
USPTO Abstract
The present disclosure provides methods of determining a response to at least one therapy by a subject having cancer, wherein the at least one therapy comprises the administration of at least one SMARCA4-targeting compound. The present disclosure also provides methods of treating a cancer in a subject, wherein the subject has been previously administered at least one therapeutically effective amount of at least one SMARCA4-targeting compound. The present disclosure also provides a method of identifying at least one SMARCA4-targeting compound. The present disclosure also provides a method of modulating an epithelial/mesenchymal state in at least one cell.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.